Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05905614 Completed - Clinical trials for Advanced Solid Tumors

Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors

Start date: November 3, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical study evaluated the safety and efficacy of SPH4336 in the treatment of advanced solid tumors.

NCT ID: NCT05731934 Completed - Clinical trials for Advanced Solid Tumors

The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors

Start date: September 15, 2020
Phase: Phase 1
Study type: Interventional

Open label, single- and multiple-dose administration, dose-exploratory clinical phase I study to evaluate the safety, tolerability and PK profile of HX301 monolactate capsules in patients with advanced malignant solid tumors and to preliminarily evaluate its antitumor efficacy.

NCT ID: NCT05498480 Completed - Clinical trials for Advanced Solid Tumors

Study of Relatlimab in Combination With Nivolumab in Chinese Participants

RELATIVITY-111
Start date: July 27, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and drug levels of relatlimab combined with nivolumab in Chinese participants with advanced solid tumors.

NCT ID: NCT05116891 Completed - Colorectal Cancer Clinical Trials

A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

Start date: September 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, multicentric, non-randomised, parallel-arm study that aims to establish the safety, tolerability, and initial efficacy of CAN04 in combination with 3 SoC chemotherapies (mFOLFOX, DTX, and G/C).

NCT ID: NCT05086848 Completed - Clinical trials for Advanced Solid Tumors

A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors

Start date: May 5, 2016
Phase: Phase 1
Study type: Interventional

This is a dose-escalation and expansion, open label, single centre, phase Ib study. In this study, the tolerability, safety, pharmacokinetics and efficacy of irinotecan hydrochloride liposome injection in combination with 5-FU/LV were studied in patients with advanced solid tumors. Meanwhile, to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of irinotecan hydrochloride liposome.

NCT ID: NCT05086822 Completed - Clinical trials for Advanced Solid Tumors

A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors

Start date: September 9, 2014
Phase: Phase 1
Study type: Interventional

This is an open label, dose-escalation and expansion, single centre, phase Ia study . In this study, the tolerability, safety, pharmacokinetics and efficacy of irinotecan hydrochloride liposome injection were studied in patients with advanced solid tumors, to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of irinotecan hydrochloride liposome.

NCT ID: NCT05017623 Completed - Clinical trials for Advanced Solid Tumors

A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors

Start date: August 26, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label, dose-escalation study of the study drug YH003 . The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of YH003 in subjects with advanced solid tumors.

NCT ID: NCT04921878 Completed - Clinical trials for Advanced Solid Tumors

A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors

Start date: July 30, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of mitoxantrone hydrochloride liposome injection in patients with advanced solid tumors.

NCT ID: NCT04911894 Completed - Clinical trials for Advanced Solid Tumors

A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors

Start date: June 21, 2021
Phase: Phase 1
Study type: Interventional

This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and primary efficacy of IBI321 in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable.

NCT ID: NCT04911881 Completed - Clinical trials for Advanced Solid Tumors

A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors

Start date: June 24, 2021
Phase: Phase 1
Study type: Interventional

This first-in-human open-label,dose-escalation study is designed to evaluate the safety, tolerability, and primary efficacy of IBI321 in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable.